Skip to main content
PIRAMAL PHARMA LIMITED logo

PIRAMAL PHARMA LIMITED — Investor Relations & Filings

Ticker · PPLPHARMA ISIN · INE0DK501011 LEI · 3358006D6AL7PZ4U9T51 BSE.NS Manufacturing
Open in API
Filings indexed 363 across all filing types
Latest filing 2026-01-28 Capital/Financing Update
Country IN India
Listing BSE.NS PPLPHARMA

About PIRAMAL PHARMA LIMITED

https://www.piramalpharma.com/

Piramal Pharma Limited provides a broad range of products and services across the drug lifecycle through three main business segments: Piramal Pharma Solutions, Piramal Critical Care, and Consumer Healthcare. Piramal Pharma Solutions operates as an integrated Contract Development and Manufacturing Organization (CDMO), offering end-to-end services from drug discovery and development to commercial manufacturing of APIs and formulations. Piramal Critical Care focuses on complex hospital generics, holding a significant global market share in inhalation anesthetics, including Sevoflurane and Isoflurane, as well as injectable anesthesia and pain management therapies. The Consumer Healthcare division manages a diverse portfolio of over-the-counter brands such as Saridon, Lacto Calamine, and Tetmosol. The company leverages an extensive global manufacturing network to deliver specialized healthcare solutions worldwide.

Recent filings

Filing Released Lang Actions
Arrangements for strategic, technical, manufacturing, or marketing tie up
Capital/Financing Update Classification · 95% confidence The document is a disclosure under Regulation 30 of the SEBI Listing Regulations about the acquisition of a branded product (Kenalog) by a subsidiary of Piramal Pharma Limited. It is an announcement of a transaction (acquisition) and does not contain financial statements, detailed financial analysis, or management discussion. The document is relatively short (2761 characters) and serves as an update on a capital transaction. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2026-01-28 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short notice dated January 21, 2026, addressed to stock exchanges (BSE and NSE) regarding the schedule of upcoming analyst and institutional investor meetings. It references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, specifically Regulation 30(6), which pertains to disclosure of material events or information. The content is purely an announcement of scheduled investor meetings, with no financial data, analysis, or detailed report content. The document length is only 1979 characters, indicating it is a brief announcement rather than a full report or presentation. Therefore, this document fits best under the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other specific categories.
2026-01-21 English
Shareholders meeting
Declaration of Voting Results & Voting Rights Announcements Classification · 98% confidence The document is a formal communication addressed to stock exchanges regarding the disclosure of e-voting results and the scrutinizer's report on a postal ballot. It includes detailed voting results for a special resolution concerning the appointment of an independent director. The document references compliance with SEBI regulations and the Companies Act, and it contains the scrutinizer's report as an annexure. There are no financial statements or management discussion of financial results, nor is this an announcement of earnings or a report publication notice. The content clearly pertains to the official results of shareholder voting at a general meeting conducted via postal ballot and e-voting. Therefore, this document fits the category of "Declaration of Voting Results & Voting Rights Announcements" (DVA). The document length and detail support a high confidence level.
2026-01-16 English
Board Meeting — Board Meeting Intimation
Regulatory Filings
2026-01-16 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a notification about an upcoming conference call to discuss Q3 and 9M FY2026 earnings results. It includes details such as date, time, dial-in numbers, and registration link for the call. There are no actual financial results or detailed analysis presented in the text. The document is an announcement of the conference call event rather than the transcript or the earnings release itself. Therefore, it fits the category of a Call Transcript (CT) announcement, but since it is only an intimation of the call and not the transcript, it is best classified as a Regulatory Filing (RNS) as a fallback for such announcements that do not fit other categories. The document length is short (3355 characters), supporting that it is an announcement rather than a full report or transcript.
2026-01-16 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a short notice dated 16th January 2026 from Piramal Pharma Limited addressed to stock exchanges (BSE and NSE). It informs about an upcoming Board Meeting scheduled for 28th January 2026 to consider and approve the unaudited financial results for the quarter and nine months ended 31st December 2025. It also mentions the closure of the trading window for securities dealing. The document is brief (1656 characters) and serves as an announcement of a future event (board meeting and financial results approval), not the financial results report itself. It does not contain any financial data or detailed analysis. Therefore, it is best classified as a Regulatory Filing (RNS) under SEBI Listing Regulations, specifically Regulation 29, which deals with board meeting intimation and disclosures. It is not an Interim/Quarterly Report (IR) because it does not contain the actual financial results, only the notice of their upcoming approval.
2026-01-16 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.